Jump to content

Search results

Page title matches

  • |title=TTFields / Optune Lua for Mesothelioma: STELLAR Trial, FDA Approval & Treatment Guide ...mprehensive guide to Tumor Treating Fields (TTFields) therapy using Optune Lua for malignant pleural mesothelioma. Covers STELLAR trial results (18.2-mont ...
    64 KB (8,231 words) - 09:57, 6 April 2026

Page text matches

  • |title=TTFields / Optune Lua for Mesothelioma: STELLAR Trial, FDA Approval & Treatment Guide ...mprehensive guide to Tumor Treating Fields (TTFields) therapy using Optune Lua for malignant pleural mesothelioma. Covers STELLAR trial results (18.2-mont ...
    64 KB (8,231 words) - 09:57, 6 April 2026
  • * '''Tumor Treating Fields Approved:''' May 2019 (Optune Lua) | style="padding:10px; " | '''FDA approves Tumor Treating Fields (Optune Lua)''' ...
    20 KB (2,490 words) - 20:57, 20 February 2026
  • | style="padding:10px;" | TTFields (Optune Lua) ...
    14 KB (1,830 words) - 09:56, 6 April 2026
  • === Tumor Treating Fields (TTFields / Optune Lua) === ...t 150 kHz to disrupt cancer cell division. The NovoTTF-100L device (Optune Lua) was approved via Humanitarian Device Exemption in May 2019 based on the ST ...
    55 KB (6,918 words) - 12:35, 6 April 2026
  • * '''Tumor Treating Fields:''' Optune Lua device approved 2019 * Optune Lua device ...
    25 KB (3,138 words) - 20:56, 20 February 2026
  • | style="padding:10px;" | FDA approval of Optune Lua * '''Tumor Treating Fields:''' Optune Lua with chemotherapy (approved May 2019) ...
    38 KB (4,755 words) - 03:42, 9 March 2026
  • * [[TTFields Optune Lua]] ...
    27 KB (3,530 words) - 04:00, 9 March 2026
  • ...der-bottom:1px solid #dee2e6;" | '''[[TTFields_Optune_Lua|TTFields (Optune Lua)]]''' * [[TTFields_Optune_Lua|TTFields / Optune Lua for Mesothelioma]] ...
    67 KB (8,763 words) - 09:18, 6 April 2026
  • '''Tumor Treating Fields (TTFields):''' The Optune Lua device, approved via the FDA's Humanitarian Device Exemption pathway, deliv * Tumor Treating Fields (TTFields/Optune Lua) combined with chemotherapy achieved median OS of 18.2 months in the single ...
    59 KB (7,425 words) - 01:11, 6 April 2026
  • '''Tumor Treating Fields (TTFields):''' The FDA-approved Optune Lua device costs approximately $21,000 per month based on manufacturer pricing. ...
    39 KB (4,954 words) - 23:00, 8 March 2026
  • === Tumor Treating Fields (TTFields/Optune) === ...inition:''' Tumor Treating Fields (TTFields), delivered through the Optune Lua device, is a novel treatment that uses low-intensity alternating electric f ...
    216 KB (26,444 words) - 23:30, 23 January 2026
  • ...herapy]], [[CAR-T Cell Therapy|CAR-T cell therapy]], and [[TTFields Optune Lua|tumor treating fields]] — will require updated protocols for managing novel ...
    71 KB (9,109 words) - 09:57, 6 April 2026
  • * [[TTFields_Optune_Lua|TTFields / Optune Lua for Mesothelioma]] ...
    66 KB (8,673 words) - 02:53, 4 March 2026
  • '''Tumor Treating Fields (TTFields/Optune Lua)''' remains approved only under the Humanitarian Device Exemption pathway ( ...
    62 KB (7,831 words) - 01:11, 6 April 2026